Elizabeth S. Klings MD
Professor, Pulmonary, Allergy, Sleep & Critical Care Medicine
72 E. Concord Street | (617) 638-8679elizabeth.klings@bmc.org
klingon@bu.edu
Sections
Pulmonary, Allergy, Sleep & Critical Care Medicine
Centers
Center of Excellence in Sickle Cell Disease
Pulmonary Center
Evans Center for Interdisciplinary Biomedical Research
Biography
Dr. Klings is an Associate Professor in the Department of Medicine. She is the Director of the Center for Excellence in Sickle Cell Disease and the Director of the Pulmonary Hypertension at BUSM/Boston Medical Center. She has an outpatient clinical practice focused on patients with pulmonary hypertension and those with pulmonary complications of sickle cell disease. She attends in the Medical Intensive Care Unit and on the Pulmonary Hypertension Consultation Service at Boston Medical Center. As Director of the largest sickle cell center in New England, Dr. Klings has created numerous new clinical programs for our patients and has expanded the clinical trials program.
Dr. Klings’ research since fellowship has focused on pathogenesis of pulmonary vascular complications of sickle cell disease. She is an NIH-funded Principal Investigator .in the Pulmonary Center collaborating with numerous other investigators across the medical campus. She has phenotypically screened over 200 sickle cell patients at Boston Medical Center for the presence of pulmonary hypertension and currently investigating the roles of disease modulators including sleep-disordered breathing and venous thromboembolism in the endothelial and vascular dysfunction these patients experience. Known internationally as a leader in the care and treatment of patients with sickle cell disease, she was first author of the American Thoracic Society sponsored clinical guidelines for Diagnosis and Treatment of Pulmonary Hypertension in Sickle Cell Disease. She recently chaired an ATS sponsored workshop to define clinical and research priorities in sickle cell lung disease and serves on the NHLBI Sickle Cell Disease Advisory Committee.
Websites
Pulmonary, Allergy, Sleep & Critical Care Medicine Faculty
Education
MD, New York University School of Medicine
Biology, BA, New York University
Publications
Gladwin MT, Gordeuk VR, Desai PC, Minniti C, Novelli EM, Morris CR, Ataga KI, De Castro L, Curtis SA, El Rassi F, Ford HJ, Harrington T, Klings ES, Lanzkron S, Liles D, Little J, Nero A, Smith W, Taylor JG, Baptiste A, Hagar W, Kanter J, Kinzie A, Martin T, Rafique A, Telen MJ, Lalama CM, Kato GJ, Abebe KZ. Riociguat in patients with sickle cell disease and hypertension or proteinuria (STERIO-SCD): a randomised, double-blind, placebo controlled, phase 1-2 trial. Lancet Haematol. 2024 Mar 27. PMID: 38554715.
Published on 3/15/2024Siskind SM, Johnson TY, Klings ES, Modzelewski KL. Diabetes Screening Rates and Practices in Patients With Sickle Cell Disease. Diabetes Care. 2024 Mar 15. PMID: 38489046.
Published on 3/11/2024Zheng R, Solomon A, DiLorenzo M, Rajendran I, Park J, Dhongade V, Garcia MA, Eberhardt RT, Sloan JM, Weinberg J, Klings ES. The Association of Anticoagulation Intensity with Outcomes in Hospitalized COVID-19 Patients. Adv Hematol. 2024; 2024:8838308. PMID: 38500844.
Published on 1/10/2024Barberà J, Jansa P, Klings E, Ristic A, Keogh A, Solum D, Rao Y, Grover R, Saib I, Sood N. Ralinepag Phase II Open-Label Extension Study in Patients with Pulmonary Arterial Hypertension. Adv Ther. 2024 Mar; 41(3):1062-1074. PMID: 38198043.
Published on 12/19/2023Lui JK, Cozzolino M, Winburn M, Trojanowski MA, Wiener RS, LaValley MP, Bujor AM, Gopal DM, Klings ES. Role of Left Ventricular Dysfunction in Systemic Sclerosis-Related Pulmonary Hypertension. Chest. 2023 Dec 19. PMID: 38128607.
Published on 11/13/2023Lui JK, Gillmeyer KR, Sangani RA, Smyth RJ, Gopal DM, Trojanowski MA, Bujor AM, Soylemez Wiener R, LaValley MP, Klings ES. A Clinical Decision Tool for Risk Stratifying Patients with Systemic Sclerosis-Related Pulmonary Hypertension. Lung. 2023 Dec; 201(6):565-569. PMID: 37957388.
Published on 6/17/2023Vakhshoorzadeh J, Lui JK, Sangani RA, Trojanowski MA, Bujor AM, LaValley MP, Klings ES. Emphysema and interstitial lung disease in systemic sclerosis-related pulmonary hypertension. Respir Med. 2023 Sep; 216:107333. PMID: 37336329.
Published on 1/20/2023Lui JK, Sangani RA, Gillmeyer KR, Vakhshoorzadeh J, Trojanowski MA, Bujor AM, Gopal DM, Wiener RS, LaValley MP, Klings ES. Correction to: Hemodynamic Response to Oral Vasodilator Therapy in Systemic Sclerosis-Related Pulmonary Hypertension. Cardiovasc Drugs Ther. 2023 Jan 20. PMID: 36662449.
Published on 1/18/2023Lui JK, Gillmeyer KR, Sangani RA, Smyth RJ, Gopal DM, Trojanowski MA, Bujor AM, Soylemez Wiener R, LaValley MP, Klings ES. A Multimodal Prediction Model for Diagnosing Pulmonary Hypertension in Systemic Sclerosis. Arthritis Care Res (Hoboken). 2023 Jul; 75(7):1462-1468. PMID: 35678779.
Published on 1/6/2023Lui JK, Sangani RA, Gillmeyer KR, Vakhshoorzadeh J, Trojanowski MA, Bujor AM, Gopal DM, Wiener RS, LaValley MP, Klings ES. Hemodynamic Response to Oral Vasodilator Therapy in Systemic Sclerosis-Related Pulmonary Hypertension. Cardiovasc Drugs Ther. 2023 Jan 06. PMID: 36607535.
Media Mentions
Published on 12/12/2023
BU Researchers Helped Develop the First FDA-Approved Gene Therapies to Treat Sickle Cell Disease
Published on 7/15/2022
Athletes gearing up for Boston Triathlon on July 24
Published on 4/20/2021
New Strategies Confront the Critical Need to Improve Sickle Cell Disease Care
Published on 3/3/2021
Doctors: Battling virus 'has definitely been challenging'
Published on 6/16/2020
Reducing Care Fragmentation in Sickle Cell Disease
View full list of 5 media mentions.